Navigation Links
Heska Introduces New Lactate Meter Analyzer
Date:3/1/2011

LOVELAND, Colo., March 1, 2011 /PRNewswire/ -- Heska Corporation (Nasdaq: HSKA; "Heska"), a leading provider of advanced diagnostic and specialty products to veterinarians, today announced the addition of a lactate meter analyzer to its portfolio of in-clinic blood analyzers.

(Logo:  http://photos.prnewswire.com/prnh/20000622/HESKALOGO)

Among other features, the handheld portable analyzer is used to measure lactate, and is ideal for both in-clinic and field use. It provides a lactate assay solution to complement the VitalPath® and DRI-CHEM® Analyzers for complete blood analysis.

"Heska is pleased to announce another product collaboration with Roche," commented Michael McGinley, President and Chief Operating Officer of Heska. "This new lactate meter analyzer will complement Heska's full range of blood analyzers, and is another example of our commitment to innovation within the veterinary industry."

About Heska

Heska Corporation (Nasdaq: HSKA) sells advanced veterinary diagnostic and other specialty veterinary products. Heska's state-of-the-art offerings to its customers include diagnostic and monitoring instruments and supplies as well as single use, point-of-care tests, vaccines and pharmaceuticals. The company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians. For further information on Heska and its products, visit the company's website at www.heska.com.

Forward-Looking Statements

This announcement contains forward-looking statements regarding Heska's future financial and operating results. These statements are based on current expectations and are subject to a number of risks and uncertainties including risks related to Heska's reliance on a third party, Roche Diagnostics, to supply the lactate meter analyzers and affiliated consumables of appropriate quality and quantity; competition; uncertainties regarding Heska's ability to successfully commercialize new products; uncertainties regarding Heska's ability to market, sell and distribute products; uncertainties regarding the performance of products in field use as compared to current expectations; uncertainties regarding the outcome of any collaborations between Heska and any third party, including Roche; risks related to relying on the reputation of Heska, Roche or any other entity, which is subject to interpretation and may change over time; uncertainties related to the future development efforts of any third party; and the risks set forth in Heska's filings and future filings with the Securities and Exchange Commission, including those set forth in Heska's Annual Report on Form 10-K/A for the year ended December 31, 2009 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2010.


'/>"/>
SOURCE Heska Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Heska to Present Live, Online at RetailInvestorConferences.com
2. Heska to Present at Sidoti Micro-Cap Conference
3. Heska Corporation Announces Stockholder Approval of Reverse Split
4. Webcast Alert: Heska Corporations Special Meeting of Stockholders Webcast
5. Heska Corporation Awards $25,000 Grand Prize to Pets Forever
6. Heska Announces Q310 Results
7. Heska Announces First Installation of New Blood Gas & Electrolyte Analyzer
8. Heska to Present at SunTrust Robinson Humphrey 1st Annual Veterinary Conference
9. Webcast Alert: Heska Announces Fourth Quarter and Year-End 2009 Earnings Conference Call Webcast
10. Heska Announces Extension of Credit Agreement With Wells Fargo
11. Heska Announces Supply Agreement With Roche Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/8/2017)...  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company ... results for the second quarter ended June 30, 2017. ... 2017 and to date: ... the Company,s lead project, BL-8040: Announced ... as novel stem cell mobilization treatment for autologous bone-marrow ...
(Date:8/7/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent specialty ... 2017.  All comparisons, unless otherwise noted, are to the quarter ... Second Quarter 2017 Highlights include: ... of 3.5% Total prescriptions dispensed of 220,000, ... versus 7.6% Gross profit per prescription ...
(Date:8/2/2017)... Aug. 2, 2017 Fenita J. ... as a Pinnacle Lifetime Professional in the Field ... Manager at Turing Pharmaceuticals, AG. Her skills and ... relationship building.                ... 25 years of experience as a highly successful ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... August 16, 2017 , ... Paul Vitenas, MD, FACS , ... Top Doctor. The annual list identifies the nation’s top physicians, in a variety of ... it to the top of Castle Connolly’s coveted ranking. , Castle Connolly is the ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... A global ... has successfully opened clubfoot clinics in all 29 Indian states—bringing the country one step ... in Kangra, Himachal Pradesh, the nonprofit organization is on track to enroll 10,000 children ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... the endoscope after every reprocessing cycle, both between patient procedures and before storage, ... infections. Drying is as important to the prevention of disease transmission and nosocomial ...
(Date:8/16/2017)... ... August 16, 2017 , ... Fusion Flix Inc., a ... programming over four countries and millions of viewers in a partnership with the Amazon ... buy On-Demand and fully available on Blu Ray disc in 2018. Proceeds will be ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... eBook, 9781498499620    ) shares that during the time of a cancer diagnosis, surgery and ... God's love, and all the many ways God shows love to those who ...
Breaking Medicine News(10 mins):